Research programme: ophthalmology therapeutic - DURECT/Santen Pharmaceutical
Latest Information Update: 05 Jan 2015
At a glance
- Originator Santen Pharmaceutical
- Developer DURECT Corporation; Santen Pharmaceutical
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Eye disorders
Most Recent Events
- 16 Dec 2014 Preclinical trials in Eye disorders in Japan (Ophthalmic)